MA30780B1 - Composes et procedes associes a des agents etiquetes 18f - Google Patents

Composes et procedes associes a des agents etiquetes 18f

Info

Publication number
MA30780B1
MA30780B1 MA31764A MA31764A MA30780B1 MA 30780 B1 MA30780 B1 MA 30780B1 MA 31764 A MA31764 A MA 31764A MA 31764 A MA31764 A MA 31764A MA 30780 B1 MA30780 B1 MA 30780B1
Authority
MA
Morocco
Prior art keywords
compounds
methods associated
label agents
label
agents
Prior art date
Application number
MA31764A
Other languages
English (en)
French (fr)
Inventor
Lutz Lehmann
Ananth Srinivasan
Thomas Brumby
Detlev Suelzle
Timo Stellfeld
Keith Graham
Mylene Karramkam
Simon Ametamey
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP06090166A external-priority patent/EP1897885A1/en
Priority claimed from EP07090079A external-priority patent/EP1985624A3/en
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of MA30780B1 publication Critical patent/MA30780B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/655—Somatostatins
    • C07K14/6555—Somatostatins at least 1 amino acid in D-form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57545—Neuropeptide Y

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
MA31764A 2006-09-08 2009-04-06 Composes et procedes associes a des agents etiquetes 18f MA30780B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06090166A EP1897885A1 (en) 2006-09-08 2006-09-08 Compounds and methods for F labelled agents
EP07090079A EP1985624A3 (en) 2007-04-23 2007-04-23 Single step method of radiofluorination of biologically active compounds or biomolecules

Publications (1)

Publication Number Publication Date
MA30780B1 true MA30780B1 (fr) 2009-10-01

Family

ID=39031005

Family Applications (1)

Application Number Title Priority Date Filing Date
MA31764A MA30780B1 (fr) 2006-09-08 2009-04-06 Composes et procedes associes a des agents etiquetes 18f

Country Status (20)

Country Link
US (1) US8557776B2 (enExample)
EP (5) EP2279759A3 (enExample)
JP (2) JP5603074B2 (enExample)
KR (1) KR20090058553A (enExample)
AR (1) AR062726A1 (enExample)
AU (1) AU2007294124A1 (enExample)
BR (1) BRPI0716554A2 (enExample)
CA (2) CA2662449A1 (enExample)
CL (1) CL2007002620A1 (enExample)
CO (1) CO6150196A2 (enExample)
CR (1) CR10654A (enExample)
IL (4) IL197363A0 (enExample)
MA (1) MA30780B1 (enExample)
MX (1) MX2009002492A (enExample)
NO (1) NO20091428L (enExample)
PE (1) PE20080850A1 (enExample)
RU (1) RU2009112716A (enExample)
TN (1) TN2009000063A1 (enExample)
TW (1) TW200829277A (enExample)
WO (1) WO2008028688A2 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0716554A2 (pt) 2006-09-08 2013-09-24 Bayer Schering Pharma Ag compostos de mÉtodos para agentes rotulados de 18f
BRPI0721424A2 (pt) * 2007-03-01 2014-03-25 Bayer Schering Pharma Aktiengesellschaft Métodos de radiofluoração
GB201013808D0 (en) 2010-08-18 2010-09-29 Ge Healthcare Ltd Peptide radiotracer compositions
WO2012094334A1 (en) * 2011-01-04 2012-07-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services One-step 18f labeling of biological substrates and uses of 18f labeled biological substrates
EP2717985A4 (en) * 2011-06-09 2015-02-25 Ge Healthcare Ltd DEVICE AND METHOD FOR DISTILLATION
SMT202300035T1 (it) * 2013-03-15 2023-05-12 Cancer Targeted Tech Llc Metodi per preparare agenti di pet imaging marcati con 18f indirizzati al psma e metodi diagnostici con gli stessi
GB201314936D0 (en) 2013-08-21 2013-10-02 Ge Healthcare Ltd Radiolabelling method
GB201322456D0 (en) 2013-12-18 2014-02-05 Ge Healthcare Ltd Radiotracer compositions and methods
EP3129493B1 (en) 2014-04-09 2021-07-07 The Scripps Research Institute Import of unnatural or modified nucleoside triphosphates into cells via nucleic acid triphosphate transporters
WO2018152339A1 (en) * 2017-02-17 2018-08-23 Yale University Radiolabeled pharmaceuticals and methods of making and using same
TWI821192B (zh) 2017-07-11 2023-11-11 美商新索思股份有限公司 非天然核苷酸之導入及其方法
IL321812A (en) 2017-08-03 2025-08-01 Synthorx Inc Cytokine complexes for the treatment of autoimmune diseases
CN112930180A (zh) * 2018-04-20 2021-06-08 通用医疗公司 用于跨血脑屏障递送的乙酰化前药
MA54952A (fr) 2019-02-06 2022-05-11 Synthorx Inc Conjugués d'il-2 et méthodes d'utilisation de ceux-ci
CN113150065B (zh) * 2021-03-11 2022-07-08 武汉英纳氏药业有限公司 一种合成肽及其应用
US20240277876A1 (en) * 2021-05-20 2024-08-22 The Regents Of The University Of California Pet imaging tracers
WO2024204842A1 (ja) 2023-03-31 2024-10-03 日産化学株式会社 ピラゾール化合物及び有害生物防除剤

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5084555A (en) * 1989-08-21 1992-01-28 The Administrators Of The Tulane Educational Fund An octapeptide bombesin analog
WO1989002897A1 (en) * 1987-09-24 1989-04-06 The Administrators Of The Tulane Educational Fund Therapeutic peptides
US5723578A (en) * 1987-09-24 1998-03-03 The Administrators Of Tulane Educational Fund Peptide analogs of bombesin
JP2919889B2 (ja) * 1988-10-14 1999-07-19 アドミニストレイターズ オブ ザ テューレイン エデュケイショナル ファンド 治療用ペプチド
WO1990015153A1 (en) * 1989-06-02 1990-12-13 Georgetown University A method for the detection of anti-streptokinase antibodies
US6232071B1 (en) 1990-06-11 2001-05-15 Gilead Sciences, Inc. Tenascin-C nucleic acid ligands
US5244883A (en) * 1990-11-29 1993-09-14 The Administrators Of The Tulane Educational Fund Nonapeptide bombesin antagonists
TW432073B (en) * 1995-12-28 2001-05-01 Pfizer Pyrazolopyridine compounds
EP1042280A2 (en) 1997-12-24 2000-10-11 Vertex Pharmaceuticals Incorporated Prodrugs of aspartyl protease inhibitors
AU2010299A (en) 1997-12-24 1999-07-19 Vertex Pharmaceuticals Incorporated Prodrugs os aspartyl protease inhibitors
AU2012199A (en) 1997-12-24 1999-07-19 Vertex Pharmaceuticals Incorporated Prodrugs of aspartyl protease inhibitors
US6436989B1 (en) 1997-12-24 2002-08-20 Vertex Pharmaceuticals, Incorporated Prodrugs of aspartyl protease inhibitors
US6639076B1 (en) * 1998-08-18 2003-10-28 Eli Lilly And Company Growth hormone secretagogues
CA2375920A1 (en) * 1999-06-14 2000-12-21 Eli Lilly And Company Compounds
US7115766B2 (en) * 2000-11-30 2006-10-03 Indiana University Research & Technology Corp. Nucleophilic approach for preparing radiolabeled imaging agents and associated compounds
GB0115927D0 (en) 2001-06-29 2001-08-22 Nycomed Amersham Plc Solid-phase nucleophilic fluorination
GB0206750D0 (en) 2002-03-22 2002-05-01 Amersham Plc Radiofluorination methods
AU2003220441A1 (en) * 2002-04-09 2003-10-27 Eli Lilly And Company Dipeptidic growth hormone secretagogues
EP1527086B1 (en) * 2002-08-09 2008-01-09 Astellas Pharma Europe B.V. Compounds binding to p-selectin
US20080063599A1 (en) 2002-11-18 2008-03-13 Jorge Setoain Quinquer Compounds Which Can Be Used To Diagnose And Monitor Diseases Associated With The Formation Of Amyloid Protein Fibrils
US7342095B2 (en) * 2003-02-20 2008-03-11 University Of South Florida Peptidomimetic inhibitors of STAT activity and uses thereof
GB0305704D0 (en) 2003-03-13 2003-04-16 Amersham Plc Radiofluorination methods
WO2006083424A2 (en) 2004-12-28 2006-08-10 The Trustees Of Columbia University In The City Of New York Radiolabeled compounds and uses thereof
CA2617055A1 (en) 2005-07-29 2007-02-08 Bayer Healthcare Llc Preparation and use of biphenyl amino acid derivatives for the treatment of obesity
US20080029548A1 (en) 2006-05-05 2008-02-07 Ann De Wree Fabric treatment dispensing package
BRPI0716554A2 (pt) 2006-09-08 2013-09-24 Bayer Schering Pharma Ag compostos de mÉtodos para agentes rotulados de 18f

Also Published As

Publication number Publication date
US8557776B2 (en) 2013-10-15
CR10654A (es) 2009-04-14
EP2455105A3 (en) 2012-09-05
EP2279759A3 (en) 2013-04-17
JP5603074B2 (ja) 2014-10-08
CL2007002620A1 (es) 2008-05-30
RU2009112716A (ru) 2010-10-20
PE20080850A1 (es) 2008-09-02
TN2009000063A1 (en) 2010-08-19
BRPI0716554A2 (pt) 2013-09-24
NO20091428L (no) 2009-06-03
WO2008028688A2 (en) 2008-03-13
JP2010503618A (ja) 2010-02-04
US20080292548A1 (en) 2008-11-27
IL197363A0 (en) 2011-08-01
EP2455105A2 (en) 2012-05-23
CA2662449A1 (en) 2008-03-13
EP2063918A2 (en) 2009-06-03
AU2007294124A1 (en) 2008-03-13
JP5722966B2 (ja) 2015-05-27
MX2009002492A (es) 2009-08-28
CO6150196A2 (es) 2010-04-20
EP2279759A2 (en) 2011-02-02
KR20090058553A (ko) 2009-06-09
IL211033A0 (en) 2011-04-28
EP2063918B1 (en) 2014-02-26
IL211527A0 (en) 2011-05-31
EP3056509A1 (en) 2016-08-17
TW200829277A (en) 2008-07-16
WO2008028688A3 (en) 2008-11-13
EP2289564A3 (en) 2012-11-14
EP2455105B1 (en) 2016-02-17
AR062726A1 (es) 2008-11-26
IL211526A0 (en) 2011-05-31
JP2014028813A (ja) 2014-02-13
EP2289564A2 (en) 2011-03-02
CA2858907A1 (en) 2008-03-13

Similar Documents

Publication Publication Date Title
MA31690B1 (fr) Nouveaux fongicides
MA31597B1 (fr) Nouveaux herbicides
MA31596B1 (fr) Nouveaux herbicides
MA29549B1 (fr) Arylpyrazoles substitues destines a etre utilises contre des parasites
MA55131B1 (fr) Nouveaux composés hétérocycliques
WO2008028688A3 (en) Compounds and methods for 18f labeled agents
EP1834571A4 (en) INSERTION UNIT WITH ENDOSCOPE USE
MA29816B1 (fr) Composes de benzimidazole thiophene
MA33275B1 (fr) Inhibiteurs de la replication du virus de l'immunodeficience humaine
MA31285B1 (fr) Dihydro et tetrahydro oxazolopyrimidinones substituees, preparation et utilisation de celles-ci
EP2232348A4 (en) DIAGNOSTICS FOR MASS FLOW CONTROL
EP1937312A4 (en) CHIMERIC OLIGOMER CONNECTIONS FOR MODULATING SPLICING
EP2921482A3 (en) Labeled inhibitors of prostate-specific membrane antigen (PSMA), biological evaluation, and use as imaging agents
EP2092646A4 (en) DIRECT DIGITAL INTERPOLATIVE SYNTHESIS
EP2009083A4 (en) OIL COMPOSITION
EP1740559A4 (en) ALSHEETS INHIBITORS FOR THE TREATMENT OF ALZHEIMER DISEASE SUITABLE 1,3,5-SUBSTITUTED PHENYL DERIVATIVE COMPOUNDS
MA30912B1 (fr) Nouveaux derives de phenylsulfamoyl-benzamide en tant qu'antagonistes de la bradykinine
FR2919305B1 (fr) Vecteurs viraux adeno-associes pour l'expression de la dysferline.
MA30042B1 (fr) Composes calcilytiques
MA48594B1 (fr) Nouveaux dérivés d'éther d'isoxazolyle en tant que pam alpha5 gaba a
MA31623B1 (fr) Nouveaux herbicides
EP1758854A4 (en) PYRROLIDIN-3-YL COMPOUNDS SUITABLE AS BETA SEKRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER DISEASE
MA32985B1 (fr) Nouveaux microbiocides
EP2200679A4 (en) SOLDERABLE CONNECTION MECHANISM
MA30824B1 (fr) Radiofluration